Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer.

Barlin, Joyce N; Dao, Fanny; Bou Zgheib, Nadim; Ferguson, Sarah E; Sabbatini, Paul J; Hensley, Martee L; Bell-McGuinn, Katherine M; Konner, Jason; Tew, William P; Aghajanian, Carol; Chi, Dennis S

Barlin, Joyce N; Dao, Fanny; Bou Zgheib, Nadim; Ferguson, Sarah E; Sabbatini, Paul J; Hensley, Martee L; Bell-McGuinn, Katherine M; Konner, Jason; Tew, William P; Aghajanian, Carol; Chi, Dennis S.

Affiliation

Barlin JN; Gynecology Service, Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, NY 10065, USA.

Gynecol Oncol ; 125(3): 621-4, 2012 Jun.

Article in En | MEDLINE | ID: mdl-22446622

Subject(s)

Antineoplastic Combined Chemotherapy Protocols/administration & dosage; Fallopian Tube Neoplasms/drug therapy; Ovarian Neoplasms/drug therapy; Peritoneal Neoplasms/drug therapy; Adult; Aged; Ambulatory Care/methods; Cisplatin/administration & dosage; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Fallopian Tube Neoplasms/pathology; Fallopian Tube Neoplasms/surgery; Female; Humans; Infusions, Intravenous; Infusions, Parenteral; Middle Aged; Neoplasm Staging; Ovarian Neoplasms/pathology; Ovarian Neoplasms/surgery; Paclitaxel/administration & dosage; Peritoneal Neoplasms/pathology; Peritoneal Neoplasms/surgery; Retrospective Studies; Survival Rate; Treatment Outcome; Young Adult

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Database: MEDLINE Main subject: Ovarian Neoplasms / Peritoneal Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Fallopian Tube Neoplasms Type of study: Observational_studies / Risk_factors_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Gynecol Oncol Year: 2012 Type: Article Affiliation country: United States

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google